Executive Summary
Phase 2 TransCon IL-2 beta/gamma prodrug in oncology (IL-Believe program), with focus on platinum-resistant ovarian cancer and various solid tumors
Target Biology
No target biology data available.
Clinical Data
No clinical trial data available.
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| TransCon IL-2 β/γ IL-Believe program update (PROC OS) | Q4 2026 | — | — |